Selected References:
- Affendi Raja RA, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. BMC Gastroenterology, 22:219-229.
- Courtney TP, et al. 1988. Excretion of famotidine in breast milk. Br J Clin Pharmacol, 626:639P.
- Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol, 19:453-458.
- Hagemann, TM, 1998. Gastrointestinal medications and breastfeeding. Journal of Human Lactation, 14(3):259–262.
- Kallen B, 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Journal of Obstetrics and Gynecology, 105:877-881.
- Magee LA, et al.1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci, 41(6):1145-1149.
- Matok I, et al. 2010. The safety of H (2)-blockers use during pregnancy. J Clin Pharmacol, 50(1):81-87.
- Orenstein SR, Shalaby TM, Devandry SN, et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther, 7(9):1097-107.
- Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol, 12:19-22.
- Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol., 204: 72-73.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol, 56(1):116-123.
